DK3172213T3 - Makrocykliske kinasehæmmere og anvendelser deraf - Google Patents
Makrocykliske kinasehæmmere og anvendelser deraf Download PDFInfo
- Publication number
- DK3172213T3 DK3172213T3 DK15824907.8T DK15824907T DK3172213T3 DK 3172213 T3 DK3172213 T3 DK 3172213T3 DK 15824907 T DK15824907 T DK 15824907T DK 3172213 T3 DK3172213 T3 DK 3172213T3
- Authority
- DK
- Denmark
- Prior art keywords
- macrocyclic
- inhibitors
- chinese
- macrocyclic chinese
- chinese inhibitors
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/08—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462027099P | 2014-07-21 | 2014-07-21 | |
| PCT/US2015/041360 WO2016014551A1 (en) | 2014-07-21 | 2015-07-21 | Macrocyclic kinase inhibitors and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3172213T3 true DK3172213T3 (da) | 2021-12-13 |
Family
ID=55163644
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK15824907.8T DK3172213T3 (da) | 2014-07-21 | 2015-07-21 | Makrocykliske kinasehæmmere og anvendelser deraf |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US10457691B2 (da) |
| EP (1) | EP3172213B1 (da) |
| AU (1) | AU2015292827B2 (da) |
| CA (1) | CA2954187C (da) |
| DK (1) | DK3172213T3 (da) |
| WO (1) | WO2016014551A1 (da) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2519517B1 (en) | 2009-12-29 | 2015-03-25 | Dana-Farber Cancer Institute, Inc. | Type ii raf kinase inhibitors |
| EP2822935B1 (en) | 2011-11-17 | 2019-05-15 | Dana-Farber Cancer Institute, Inc. | Inhibitors of c-jun-n-terminal kinase (jnk) |
| GB201204384D0 (en) | 2012-03-13 | 2012-04-25 | Univ Dundee | Anti-flammatory agents |
| EP2909194A1 (en) | 2012-10-18 | 2015-08-26 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinase 7 (cdk7) |
| WO2014063061A1 (en) | 2012-10-19 | 2014-04-24 | Dana-Farber Cancer Institute, Inc. | Hydrophobically tagged small molecules as inducers of protein degradation |
| US10000483B2 (en) | 2012-10-19 | 2018-06-19 | Dana-Farber Cancer Institute, Inc. | Bone marrow on X chromosome kinase (BMX) inhibitors and uses thereof |
| US20160264551A1 (en) | 2013-10-18 | 2016-09-15 | Syros Pharmaceuticals, Inc. | Heteroaromatic compounds useful for the treatment of prolferative diseases |
| EP3057956B1 (en) | 2013-10-18 | 2021-05-05 | Dana-Farber Cancer Institute, Inc. | Polycyclic inhibitors of cyclin-dependent kinase 7 (cdk7) |
| WO2015164614A1 (en) | 2014-04-23 | 2015-10-29 | Dana-Farber Cancer Institute, Inc. | Janus kinase inhibitors and uses thereof |
| WO2015164604A1 (en) | 2014-04-23 | 2015-10-29 | Dana-Farber Cancer Institute, Inc. | Hydrophobically tagged janus kinase inhibitors and uses thereof |
| EP3172213B1 (en) | 2014-07-21 | 2021-09-22 | Dana-Farber Cancer Institute, Inc. | Macrocyclic kinase inhibitors and uses thereof |
| WO2016014542A1 (en) | 2014-07-21 | 2016-01-28 | Dana-Farber Cancer Institute, Inc. | Imidazolyl kinase inhibitors and uses thereof |
| AU2015300782B2 (en) | 2014-08-08 | 2020-04-16 | Dana-Farber Cancer Institute, Inc. | Uses of salt-inducible kinase (SIK) inhibitors |
| WO2016105528A2 (en) | 2014-12-23 | 2016-06-30 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinase 7 (cdk7) |
| US10550121B2 (en) | 2015-03-27 | 2020-02-04 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinases |
| WO2016201370A1 (en) | 2015-06-12 | 2016-12-15 | Dana-Farber Cancer Institute, Inc. | Combination therapy of transcription inhibitors and kinase inhibitors |
| EP4019515A1 (en) | 2015-09-09 | 2022-06-29 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinases |
| DK3778578T3 (da) | 2016-03-11 | 2022-06-20 | Univ California | Immunoproteasominhibitoranaloger til behandling af inflammatoriske sygdomme |
| KR20190075043A (ko) | 2016-07-05 | 2019-06-28 | 더 브로드 인스티튜트, 인코퍼레이티드 | 비시클릭 우레아 키나제 억제제 및 그의 용도 |
| WO2018053373A1 (en) | 2016-09-16 | 2018-03-22 | The General Hospital Corporation | Uses of satl-inducible kinase (sik) inhibitors for treating osteoporosis |
| US11426406B2 (en) | 2017-02-09 | 2022-08-30 | Georgetown University | Compositions and methods for treating lysosomal storage disorders |
| RU2019129727A (ru) * | 2017-02-28 | 2021-03-30 | Зэ Дженерал Хоспитал Корпорэйшн | Применения пиримидопиримидинонов в качестве ингибиторов sik |
| DK3391907T3 (da) | 2017-04-20 | 2020-03-09 | Iomx Therapeutics Ag | Intracellulær kinase sik3, der er associeret med resistens over for antitumorimmunresponser, og anvendelser deraf |
| EP3678662A4 (en) | 2017-09-08 | 2021-09-01 | Fronthera U.S. Pharmaceuticals LLC | APOPTOSIS SIGNAL REGULATION KINASE INHIBITORS AND THEIR USES |
| WO2019079357A1 (en) * | 2017-10-17 | 2019-04-25 | Silverback Therapeutics, Inc. | TNIK MODULATORS, CONJUGATES AND USES THEREOF |
| JOP20200152A1 (ar) * | 2017-12-19 | 2022-10-30 | Turning Point Therapeutics Inc | مركبات حلقية كبرى لعلاج مرض |
| AU2019385397A1 (en) | 2018-11-19 | 2021-04-22 | Dana-Farber Cancer Institute, Inc. | Macrocyclic inhibitors of DYRK1A |
| CA3177164A1 (en) | 2020-04-28 | 2021-11-04 | Peter Sennhenn | Bicyclic kinase inhibitors and uses thereof |
| MX2023003690A (es) | 2020-09-30 | 2023-06-15 | Asahi Kasei Pharma Corp | Compuesto macrociclico. |
| KR102524856B1 (ko) * | 2022-06-23 | 2023-04-24 | 주식회사 카나프테라퓨틱스 | 표피 성장인자 수용체 티로신 키나제에 대한 억제 활성을 갖는 신규 화합물 및 이의 용도 |
| WO2023163527A1 (ko) * | 2022-02-23 | 2023-08-31 | 주식회사 카나프테라퓨틱스 | 표피 성장인자 수용체 티로신 키나제에 대한 억제 활성을 갖는 신규 화합물 및 이의 용도 |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4231559B2 (ja) | 1997-04-23 | 2009-03-04 | オリザ油化株式会社 | リポキシゲナーゼ阻害剤 |
| WO2000024744A1 (en) | 1998-10-23 | 2000-05-04 | F. Hoffmann-La Roche Ag | Bicyclic nitrogen heterocycles |
| WO2003090688A2 (en) | 2002-04-24 | 2003-11-06 | Van Andel Research Institute | Enhancement of human epidermal melanogenesis |
| US7084270B2 (en) | 2002-08-14 | 2006-08-01 | Hoffman-La Roche Inc. | Pyrimido compounds having antiproliferative activity |
| DE10239042A1 (de) | 2002-08-21 | 2004-03-04 | Schering Ag | Makrozyclische Pyrimidine, deren Herstellung und Verwendung als Arzneimittel |
| US7112676B2 (en) | 2002-11-04 | 2006-09-26 | Hoffmann-La Roche Inc. | Pyrimido compounds having antiproliferative activity |
| MXPA05005547A (es) | 2002-11-28 | 2005-07-26 | Schering Ag | Pirimidinas inhibidoras de chk, pdk y akt, su produccion y uso como agentes farmaceuticos. |
| EP1615928A1 (en) | 2003-04-10 | 2006-01-18 | F.Hoffmann-La Roche Ag | Pyrimido compounds |
| US7504396B2 (en) | 2003-06-24 | 2009-03-17 | Amgen Inc. | Substituted heterocyclic compounds and methods of use |
| US7442698B2 (en) | 2003-07-24 | 2008-10-28 | Amgen Inc. | Substituted heterocyclic compounds and methods of use |
| MXPA06001098A (es) | 2003-07-29 | 2006-04-24 | Irm Llc | Compuestos y composiciones utiles como inhibidores de proteina cinasa. |
| MY144044A (en) | 2004-06-10 | 2011-07-29 | Irm Llc | Compounds and compositions as protein kinase inhibitors |
| GB0512324D0 (en) | 2005-06-16 | 2005-07-27 | Novartis Ag | Organic compounds |
| WO2006024545A1 (en) | 2004-09-03 | 2006-03-09 | Stichting Voor De Technische Wetenschappen | Fused bicyclic natural compounds and their use as inhibitors of parp and parp-mediated inflammatory processes |
| JP5208516B2 (ja) | 2004-12-30 | 2013-06-12 | エグゼリクシス， インコーポレイテッド | キナーゼモジュレーターとしてのピリミジン誘導体および使用方法 |
| US7479558B2 (en) | 2005-03-25 | 2009-01-20 | Glaxo Group Limited | Process for preparing pyrido[2,3-d]pyrimidin-7-one and 3,4-dihydropyrimido[4,5-d]pyrimidin-2(1H)-one derivatives |
| KR101406956B1 (ko) | 2005-12-21 | 2014-06-13 | 노파르티스 아게 | Ｆｇｆ 억제제로서의 피리미디닐 아릴 우레아 유도체 |
| AU2007254491A1 (en) | 2006-05-15 | 2007-11-29 | Irm Llc | Compositions and methods for FGF receptor kinases inhibitors |
| WO2008060248A1 (en) * | 2006-11-15 | 2008-05-22 | S*Bio Pte Ltd. | Indole sustituted pyrimidines and use thereof in the treatment of cancer |
| EP2222162B1 (en) | 2007-11-28 | 2016-11-16 | Dana-Farber Cancer Institute, Inc. | Small molecule myristate inhibitors of bcr-abl and methods of use |
| US20100056524A1 (en) | 2008-04-02 | 2010-03-04 | Mciver Edward Giles | Compound |
| WO2009152027A1 (en) | 2008-06-12 | 2009-12-17 | Merck & Co., Inc. | 5,7-dihydro-6h-pyrrolo[2,3-d]pyrimidin-6-one derivatives for mark inhibition |
| WO2010017047A1 (en) | 2008-08-05 | 2010-02-11 | Merck & Co., Inc. | Therapeutic compounds |
| JP2013508285A (ja) | 2009-10-14 | 2013-03-07 | ブリストル−マイヤーズ スクイブ カンパニー | Ｃ型肝炎の処置のための組成物 |
| CN102816162B (zh) | 2011-06-10 | 2016-04-27 | 中国科学院广州生物医药与健康研究院 | 嘧啶并嘧啶酮类化合物及其药用组合物和应用 |
| WO2013045653A1 (en) * | 2011-09-30 | 2013-04-04 | Oncodesign S.A. | Macrocyclic flt3 kinase inhibitors |
| EP2822935B1 (en) | 2011-11-17 | 2019-05-15 | Dana-Farber Cancer Institute, Inc. | Inhibitors of c-jun-n-terminal kinase (jnk) |
| GB201204384D0 (en) | 2012-03-13 | 2012-04-25 | Univ Dundee | Anti-flammatory agents |
| CN111793068A (zh) | 2013-03-15 | 2020-10-20 | 西建卡尔有限责任公司 | 杂芳基化合物和其用途 |
| US9783504B2 (en) | 2013-07-09 | 2017-10-10 | Dana-Farber Cancer Institute, Inc. | Kinase inhibitors for the treatment of disease |
| WO2016014542A1 (en) | 2014-07-21 | 2016-01-28 | Dana-Farber Cancer Institute, Inc. | Imidazolyl kinase inhibitors and uses thereof |
| EP3172213B1 (en) | 2014-07-21 | 2021-09-22 | Dana-Farber Cancer Institute, Inc. | Macrocyclic kinase inhibitors and uses thereof |
| AU2015300782B2 (en) | 2014-08-08 | 2020-04-16 | Dana-Farber Cancer Institute, Inc. | Uses of salt-inducible kinase (SIK) inhibitors |
| KR101850282B1 (ko) | 2014-11-26 | 2018-05-31 | 한국과학기술연구원 | 단백질 키나아제 저해제로 유용한 헤테로아릴아민 유도체 |
-
2015
- 2015-07-21 EP EP15824907.8A patent/EP3172213B1/en active Active
- 2015-07-21 WO PCT/US2015/041360 patent/WO2016014551A1/en active Application Filing
- 2015-07-21 AU AU2015292827A patent/AU2015292827B2/en active Active
- 2015-07-21 CA CA2954187A patent/CA2954187C/en active Active
- 2015-07-21 DK DK15824907.8T patent/DK3172213T3/da active
- 2015-07-21 US US15/327,690 patent/US10457691B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| AU2015292827A1 (en) | 2017-01-19 |
| EP3172213B1 (en) | 2021-09-22 |
| US10457691B2 (en) | 2019-10-29 |
| CA2954187A1 (en) | 2016-01-28 |
| WO2016014551A1 (en) | 2016-01-28 |
| EP3172213A1 (en) | 2017-05-31 |
| US20170204116A1 (en) | 2017-07-20 |
| EP3172213A4 (en) | 2018-01-24 |
| AU2015292827B2 (en) | 2019-11-14 |
| CA2954187C (en) | 2022-08-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3172213T3 (da) | Makrocykliske kinasehæmmere og anvendelser deraf | |
| FIC20230014I1 (fi) | Foslevodopa ja foskarbidopa | |
| DK3210977T3 (da) | Hidtil ukendt aminoalkylbenzothiazepinderivat og anvendelse deraf | |
| DK3215147T3 (da) | Neurodæmpende norketamin-forbindelser og fremgangsmåder | |
| DK3237418T3 (da) | Triazolopyrimidinforbindelser og anvendelser deraf | |
| HK1243072A1 (zh) | 布羅莫結構域抑制劑及其用途 | |
| DK3521289T3 (da) | Mnk-inhibitorer og fremgangsmåder forbundet dermed | |
| DK3201351T3 (da) | Kaloriefrie sødestoffer og fremgangsmåder til syntetisering | |
| DK3218358T3 (da) | Ifluorometyl-aminopyridiner og difluorometyl-aminopyrimidiner | |
| DK3212255T3 (da) | Selvorienterende sprøjte og sprøjtegrænseflade | |
| DK3212189T3 (da) | Substituerede chromaner og fremgangsmåde til anvendelse deraf | |
| DK3209308T3 (da) | Aktiverede bifidobakterier og fremgangsmåder til anvendelse deraf | |
| DK3333191T3 (da) | Anti-C10ORF54-antistoffer og anvendelser deraf | |
| DK3139979T3 (da) | Enhed, forstøver og fremgangsmåde | |
| DK3126388T3 (da) | Anti-EGFRvIII-antistoffer og anvendelser deraf | |
| DK3099172T3 (da) | Modificeret biologisk bekæmpelsesmiddel og anvendelser deraf | |
| DK3015526T3 (da) | Hydrofluorolefinbaseret sammensætning og anvendelse deraf | |
| DK3100523T3 (da) | Opdagelsessignaler og fremgangsmåder | |
| DK3156503T3 (da) | Mavecancer-biomarkør og detektionsfremgangsmåde | |
| DK3193611T3 (da) | Mk2-inhibitorer og anvendelser deraf | |
| DK3161139T3 (da) | Tlr-4-specifikke aptamerer og anvendelser heraf | |
| DK3089971T3 (da) | Forbindelser og fremgangsmåder til anvendelse | |
| DK3209773T3 (da) | Prolintolerante tripeptidylpeptidaser og anvendelser deraf | |
| DK3233105T3 (da) | Hidtil ukendt kombination og anvendelse | |
| DK3146320T3 (da) | Detekteringsanordning og fremgangsmåde |